Display Settings:

Format

Send to:

Choose Destination
    J Neurol. 2002 Sep;249 Suppl 2:II36-40.

    Recombinant adeno-associated viral vectors bring gene therapy for Parkinson's disease closer to reality.

    Source

    Department of Neurology, Jichi Medical School, 3311-1 Yakushiji, Minami-kawachi, Tochigi, Japan 3290498. muramats@jichi.ac.jp

    Abstract

    The recombinant adeno-associated viral (rAAV) vector is a powerful tool for delivering therapeutic genes into mammalian brains. In rodents and non-human primates, a substantial number of striatal neurons can be transduced with high titer rAAV vectors by simple stereotaxic injection. Efficient and long-term expression of genes for dopamine (DA)-synthesizing enzymes in the striatum restored local DA production and achieved behavioral recovery in animal models of Parkinson's disease (PD). Moreover, sustained expression of a glial cell line-derived neurotrophic factor gene in the striatum rescued nigral neurons and led to functional recovery in a rat model of PD, even when treatment was delayed until after the onset of progressive degeneration. These results suggest that gene therapy using rAAV vectors may become a novel and feasible treatment for PD.

    PMID:
    12375062
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Springer

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk